The overactivity bladder: Pharmacologic basis of drug treatment

Urology

Volumn 50, Issue 6 SUPPL. A, 1997, Pages 74-84

  Andersson, Karl Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CAPSAICIN; CROMAKALIM; DOPAMINE RECEPTOR STIMULATING AGENT; DOXAZOSIN; IMIPRAMINE; INDOMETACIN; MUSCARINIC AGENT; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; PHOSPHODIESTERASE INHIBITOR; PHYSOSTIGMINE; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; PROSTAGLANDIN E2; RESINIFERATOXIN; THROMBOXANE B2; TOLTERODINE; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; ION CHANNEL;

ALPHA ADRENERGIC STIMULATION; BLADDER DYSFUNCTION; BLADDER INNERVATION; CONFERENCE PAPER; DETRUSOR DYSSYNERGIA; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; NEUROTRANSMISSION; PERIPHERAL NERVE; PRIORITY JOURNAL; TREATMENT PLANNING; BLADDER; CENTRAL NERVOUS SYSTEM; INNERVATION; NEUROGENIC BLADDER; PATHOPHYSIOLOGY; REVIEW;

CENTRAL NERVOUS SYSTEM; HUMANS; ION CHANNELS; RECEPTORS, CELL SURFACE; URINARY BLADDER; URINARY BLADDER, NEUROGENIC;

EID: 0031309603     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00595-5     Document Type: Conference Paper

References (107)

1. de Groat WC, Booth AM, and Yoshimura N: Neurophysiology of micturition and its modification in animal models of human disease, in Maggi CA: The Autonomic Nervous System, Vol. 6, Nervous Control of the Urogenital System. London, Harwood Academic Publishers, 1993, pp 227-289.
2. Andersson K-E: The pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45: 253-308; 193.
3. Brading AF, and Turner WH: The unstable bladder: towards a common mechanism. Br J Urol 73: 3-8, 1994.
4. Wein AJ: Pharmacology of incontinence. Urol Clin North Am 22: 557-577, 1995.
5. Taylor MC, and Bates CP: A double-blind crossover trial of baclofen - a new treatment for the unstable bladder syndrome. Br J Urol 51: 504-505, 1979.
6. Kums JIM, and Delhaas BM: Intrathecal baclofen infusion in patients with spasticity and neurogenic bladder disease: preliminary results. World J Urol 9: 99-104, 1991.
7. Steers WD, Meythaler JM, Haworth C, Herrell D, and Park TS: Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology. J Urol 148: 1849-1855, 1992.
8. Bushman W, Steers WD, and Meythaler JM: Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurol Urodyn 12: 163-170, 1993.
9. Perucca F: The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 42: 531-543, 1996.
10. Maggi CA, Borsini F, Lecci A, Giuliani S, Meli P, Gragnani L, and Meli A: The effect of acute and chronic administration of imipramine on spinal and supraspinal micturition reflexes in rats. J Pharmacol Exp Ther 248: 278-285, 1989.
11. de Groat WC, Vizzard MA, Araki I, and Roppolo I: Spinal interneurons and preganglionic neurons in sacral autonomic reflex pathways. Progr Brain Res 107: 97-111, 1996.
12. 1-adrenoceptors. Br J Pharmacol 117: 962-966, 1996.
13. 1-adrenoceptors and uroselectivity. Prostate 30: 202-215, 1997.
14. Yoshimura N, Mizuta B, Kuno S, Sasa M, and Yoshida O: The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 32: 315-321, 1993.
15. Sillén U, Rubenson A, and Hjälmås K: On the localization and mediation of the centrally induced hyperactive urinary bladder response to L-dopa in the rat. Acta Physiol Scand 112: 137-140, 1981.
16. Kontani H, Inoue T, and Sakai T: Effects of apomorphine on urinary bladder motility in anesthetized rats. Jpn J Pharmacol 52: 59-67, 1990.
17. Kontani H, Inoue T, and Sakai T: Dopamine receptor subtypes that influence hyperactive urinary bladder response in anesthetized rats. Jpn J PHarmacol 54: 482-486, 1990.
18. Eglen RM, Hegde SS, and Watson N: Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev 48: 531-565, 1996.
19. 3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol 154: 1241-1245, 1995.
20. Kondo S, Morita T, and Tashima Y: Muscarinic cholinergic receptor subtypes in human detrusor muscle studied by labeled and nonlabeled pirenzepine, AFDX116, and 4DAMP. Urol Int 54: 150-153, 1995.
21. Yamaguchi O, Shisda K, Tamura K, Ogawa T, Fujimura T, and Ohtsuka M: Evaluation of mRNAs encoding muscarinic receptor subtyupes in human detrusor muscle. J Urol 156: 1208-1213, 1996.
22. Wang P, Luthin CR, and Ruggieri MR: Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 273: 956-959, 1995.
23. Longhurst PA, Leggett RB, and Briscoe JAK: Characterization of the functional muscarinic receptors in the rat urinary bladder. Br J Pharmacol 116: 2279-2285, 1995.
24. 3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 120: 1409-1418, 1997.
25. Newgreen DT, Anderson CWP, Carter AJ, and Naylor AM: Darifenacin - a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 14: 95-96, 1995.
26. Wallis RM, Burges RA, Cross PE, MacKenzie AR, Newgreen DT, and Quinn P: Darifenacin, a selective muscarinic M3 antagonist. Pharmacol Res 31(suppl): 54, 1995.
27. Yamamoto, T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Bsumi K, and Ohtsuka M: Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency. J Urol 154: 2174-2178, 1995.
28. Yamamoto, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, and Shinomura K: General pharmacology of the new antimuscarinic compound vamicamide. Arzeim Forsch/Drugs Res 45: 1274-1284, 1995.
29. Watson N, Reddy H, Stefanich E, and Eglen RM: Characterization of the interaction of zamifenacin at muscarinic receptors. Eur J Pharmacol 285: 135-142, 1995.
30. Nilvebrant L, Andersson K-E, Gillberg P-G, Stahl M, and Sparf B: Tolterodine - a new bladder selective antimuscarinic agent. Eur J Pharmacol 327: 195-207, 1997.
31. Stahl MMS, Ekström B, Sparf B, Mattiasson A, and Andersson K-E: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 14: 647-655, 1995.
32. Somogyi CT, and de Groat WC: Evidence for inhibitory nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. J Auton Nerv Syst 37: 89-98, 1992.
33. Somogyi CT, Tanowitz M, and de Groat WC: MI muscarinic receptor-mediated facilitation of acetylcholine release in the rat urinary bladder. J Physiol 480: 81-89, 1994.
34. Gosling JA, Gilpin SA, Dixon IS, and Gilpin CJ: Decrease in the autonomic innervation of human detrusor muscle in outflow obstruction. J Urol 136: 501-504, 1986.
35. Speakman MJ, Brading AF, Gilpin CJ, Dixon JS, Gilpin SA, and Gosling JA: Bladder outflow obstruction - a cause of denervation supersensitivity. J Urol 138: 1461-1466, 1987.
36. Sibley GNA: The physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br J Urol 60: 332-336, 1987.
37. Harrison SCV, Hunnam GR, Farman P, and Doyle PT: Bladder instability and denervation in patients with bladder outflow obstruction. Br J Urol 60: 519-522, 1987.
38. Yokoyama O, Nagano K, Kawaguchi K, and Hisazumi H: The responses of the detrusor muscle to acetylcholine in patients with infravesical obstruction. Urol Res 19: 117-121, 1991.
39. Kinder RB, and Mundy AR: Pathophysiology of idiopathic detrusor instability and detrusor hyperreflexia. An in vitro study of human detrusor muscle. Br J Urol 60: 509-515, 1987.
40. Restorick JM, and Mundy AR: The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyperreflexic human detrusor. Br J Urol 63: 32-35, 1989.
41. German K, Bedwani J, Davies J, Brading AF, and Stephenson TP: Physiological and morphometric studies into the pathophysiology of detrusor hyperreflexia in neuropathic patients. J Urol 153: 1678-1683, 1995.
42. Perlberg S, Caine M: Adrenergic response of bladder muscle in prostatic obstruction. Urology 20: 524-537, 1982.
43. Åmark P, Nergårdh A, and Kinn AC: The effect of noradrenaline on the contractile response of the urinary bladder. Scand J Urol Nephrol 20: 203-207, 1986.
44. Levin RM, Ruggieri MR, and Wein AJ: Identification of receptor subtypes in the rabbit and human urinary bladder by selective radio-ligand binding. J Urol 139: 844-848, 1988.
45. 1a-adrenoceptor in the rat, monkey and human urinary bladder and prostate. J Urol 157: 1032-1038, 1997.
46. 1-AR) antagonist tamsulosin (abstr). J Urol 157: 190, 1997.
47. Caine M: The present role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. J Urol 136: 1-4, 1986.
48. Smith DJ, and Chapple CR: In vitro response of human bladder smooth muscle in unstable obstructed male bladders: a study of pathophysiological causes. Neurourol Urodyn 13: 414-415, 1994.
49. Jensen D: Uninhibited neurogenic bladder treated with prazosin. Scand J Urol Nephrol 15: 299-233, 1981.
50. Petersen T, Husted S, and Sidenius P: Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder emptying disability. Scand J Urol Nephrol 23: 189-194, 1989.
51. Åmark P, and Nergårdh A: Influence of adrenergic agonists and antagonists on urethral pressure, bladder pressure and detrusor hyperactivity in children with myelodysplasia. Acta Paed Scand 80: 824-832, 1991.
52. Eaton AC, and Bates CP: An in vitro physiological study of normal and unstable human detrusor muscle. Br J Urol 54: 653-657, 1982.
53. Nergårdh A, Boréus LO, and Naglo AS: Characterization of the adrenergic beta-receptors in the urinary bladder of man and cat. Acta Pharmacol Toxicol 40: 14-21, 1977.
54. Larsen JJ: α-and β-adrenoceptors in the detrusor muscle and bladder base of the pig and β-adrenoceptors in the detrusor of man. Br J Urol 65: 215-222, 1979.
55. 3-adrenoceptors in the human detrusor (abstr). J Urol 157: 175, 1997.
56. Andersson K-E: Current concepts in the treatment of disorders of micturition. Drugs 35: 477-494, 1988.
57. 3-adrenoceptors. Br J Clin Pharmacol 43: 291-300, 1996.
58. 3-adrenoceptor. Trends Pharmacol Sci 17: 273-381, 1997.
59. Nishimoto T, Latifpour J, Wheeler MA, Yoshida M, and Weiss RM: Age-dependent alterations in β-adrenergic responsiveness of rat detrusor smooth muscle. J Urol 153: 1701-1705, 1995.
60. Maggi CA: Tachykinins and calcitonin gene-related peptide (CGRP) as cotransmitters released from peripheral endings of sensory nerves. Progr Neurobiol 45: 1-98, 1995.
61. Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 26: 911-944, 1995.
62. Giuliani S, Patacchini R, Barbanti C, Turini D, Rovero P, Quartara L, Giachetti A, and Maggi CA: Characterization of the tachykinin neurokinin-2 receptor in the human urinary bladder by means of selective receptor antagonists and peptidase inhibitors. J Pharmacol Exp Ther 267: 590-595, 1993.
63. Zeng XP, Moore KH, and Burcher E: Characterization of tachykinin NK2 receptors in human urinary bladder. J Urol 153: 1688-1692, 1995.
64. 2 receptors on isolated human urinary bladder, prostatic urethra and prostate. J Pharmacol Exp Ther 277: 700-705, 1996.
65. de Groat WC, Kawatani M, Hisamitsu T, Cheng C-L, Ma CP, Thor K, Steers W, and Roppolo J: Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 30(suppl): S71-S78, 1990.
66. Szallasi A: The vanilloid (capsaicin) receptor: receptor types and species differences. Gen Pharmacol 25: 223-243, 1994.
67. Maggi CA, Barbanti G, Santiciolo P, Beneforti P, Misuri D, Meli A, and Turini D: Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans. J Urol 142: 150-154, 1989.
68. Fowler CJ, Jewkes D, McDonald WI, Lynn B, and de Groat WC: Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 339: 1239, 1992.
69. Geirsson G, Fall M, and Sullivan L: Clinical and urodynamic effects of intravesical capsaicin treatment in patients with chronic traumatic spinal detrusor hypereflexia. J Urol 154: 1825-1829, 1995.
70. Chandiramani VA, Peterson T, Duthie GS, and Fowler CJ: Urodynamic changes during therapeutic intravesical instillations of capsaicin. Br J Urol 77: 792-797, 1996.
71. Craft RM, Cohen SM, and Porreca F: Long-lasting desensitization of bladder afferents following intravesical resiniferatoxin and capsaicin in the rat. Pain 61: 317-323, 1995.
72. Ishizawa O, Mattiasson A, and Andersson K-E: Urodynamic effects of intravesical resiniferatoxin and capsaicin in conscious rats with and without outflow obstruction. J Urol 154: 611-616, 1995.
73. Cruz F, Avelino A, and Coimbra A: Intravesical resiniferatoxin desensitizes bladder sensory fibers in a dose-dependent manner: a C-fos study in the rat (abstr). J Urol 157: 79, 1997.
74. Lazzeri M, Beneforti P, and Turini D: Urodynamic effects of intravesical resiniferatoxin in humans (abstr). J Urol 157: 104, 1997.
75. Jeremy JY, Tsang V, Mikhailidis DP, Rogers H, Morgan RJ, and Dandona P: Eicosanoid synthesis by human urinary bladder mucosa: pathological implications. Br J Urol 59: 36-39, 1987.
76. Maggi CA: Prostanoids as local modulators of reflex micturition. Pharmacol Res 25: 13-20, 1992.
77. Cardozo LD, Stanton SL, Robinson H, and Hole D: Evaluation on flurbiprofen in detrusor instability. Br Med J 280: 281-282, 1980.
78. Pairet M, and Engelhardt G: Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fund Clin Pharmacol 10: 1-17, 1996.
79. Vane JR: Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol 102(suppl): 9-21, 1996.
80. 2+ signalling in cultured smooth muscle cells from human bladder. Exp Physiol 81: 553-564, 1996.
81. Shapiro E, Tang R, Rosenthal E, and Lepor H: The binding and functional properties of voltage dependent calcium channel receptors in pediatric normal and myelodysplastic bladders. J Urol 146: 520-523, 1991.
82. Saito M, Gotoh M, Kato K, and Kondo A: Denervation supersensitivity of the rabbit urinary bladder to calcium ion. J Urol 142: 418-421, 1989.
83. Malmgren A, Andersson K-E, Andersson PO, Fovaeus M, and Sjögren C: effects of nifedipine and BAY K8644 on normal and hypertrophied rat detrusor. Neurourol Urodyn 7: 27-35, 1988.
84. Kura H, Yoshino M, and Yabu H: Blocking action of terodiline on calcium channels in single smooth muscle cells of the guinea pig urinary bladder. J Pharmacol Exp Ther 261: 724-729, 1992.
85. Forman A, Andersson K-E, Henriksson L, Rud T, and Ulmsten U: Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo. Acta Pharmacol Toxicol 43: 111-118, 1978.
86. Andersson K-E, Fovaeus M, Morgan E, and McLorie G: Comparative effects of five different calcium channel blockers on the atropine resistant contraction in electrically stimulated rabbit urinary bladder. Neurourol Urodyn 5: 579-586, 1986.
87. Bo X, and Burnstock G: The effects of BAY K8644 and nifedipine on the responses of rat urinary bladder to electrical field stimulation, β-y-methylene ATP and acetylcholine. Br J Pharmacol 101: 494-498, 1990.
88. Zar MA, Iravani MM, and Luheshi GN: Effect of nifedipine on the contractile responses of the isolated rat bladder. J Urol 143: 835-839, 1990.
89. Sjögren C, Andersson K-E, Husted S, Mattiasson A, and Møller-Madsen B. Atropine resistance of the transmurally stimulated isolated human bladder. J Urol 128: 1368-1371, 1982.
90. 3H]α,β-methylene adenosine 5′-triphosphate binding sites in human urinary bladder. Br J Urol 76: 297-302, 1995.
91. Palea S, Pietra C, Trist DC, Artibani W, Calpista A, and Corsi M: Evidence for the presence of both pre-and postjunctional P2-purinoceptor subtypes in human isolated urinary bladder. Br J Pharmacol 114: 35-40, 1995.
92. Wammack R, Weihe E, Dienes H-P, and Hohenfellner R: Die Neurogene Biase in vitro. Akt Urol 26: 16-18, 1995.
93. Andersson K-E: Clinical pharmacology of potassium channel openers. Pharmacol Toxicol 70: 244-254, 1992.
94. Trivedi S, Potter-Lee L, Li JH, Yasay GD, Russell K, Ohnmach CJ, Empfield JR, Trainor DA, and Kau ST: Calcium dependent K-channels in guinea pig and human urinary bladder. Biochem Biophys Res Comm 213: 404-409, 1995.
95. Edwards G, Henshaw M, Miller M, and Weston AH: Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro. Br J Pharmacol 102: 679-686, 1991.
96. Barras M, Van der Graf PH, Christophe P, and Itzchak A: Relaxant efficacy of potassium channel openers in rabbit isolated bladder and mesenteric artery (abstr). Eur J Urol 30 (suppl 2): 240, 1996.
97. Hedlund H, Andersson K-E, and Mattiasson A: Effects of pinacidil on detrusor instability in men with outlet obstruction. J Urol 146: 1345-1347, 1991.
98. Komersova K, Rogerson JW, Conway EL, Lim TC, Brown DJ, Krum H, Jackman CP, Murcoch R, and Louis WJ: The effect of levcromakalim (BRL 38227) on bladder function in patients with high spinal cord lesions. Br J Pharmacol 39: 207-209, 1995.
99. Howe BB, Halterman TJ, Yochim CL, Do ML, Pettinger SJ, Stow RB, Ohnmacht CJ, Russel K, Empfield JR, Trainor DA, et al: ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary blader. J Pharmacol Exp Ther 274: 884-890, 1995.
100. Masuda N, Uchida W, Shirai Y, Shibasaki K, Goto K, and Takenaka T: Effect of the potassium channel opener YM934 on the contractile response to electrical field stimulation in pig detrusor smooth muscle. J Urol 154: 1914-1920, 1995.
101. Li JH, Yasay GD Zografos, P, Kau ST, Ohnmacht CJ, Russell K, Empfield JR, Brown FJ, Trainor DA, Bonev AD, et al: ZENECA ZD6169 and its analogs from a novel series of anilide tertiary carbinols: in vitro KATP channel opening activity in bladder detrusor. Pharmacology 52: 33-42, 1995.
102. 3H-P1075 binding in bladder smooth muscle. Pharmacology 50: 388-397, 1995.
103. Yu YB, Fraser MO, and de Groat WC: Effect of intravesical administration of ZD6169 on the micturition reflex and on C-fos expression in the spinal cord induced by noxious bladder stimulation in the rat. Soc Neurosci 22: 93, 1996.
104. Truss M, Ückert S, Stief CG, Schulz-Knappe P, Hess R, Forssmann W-G, and Jonas U: Porcine detrusor cyclic nucleotide phosphodiesterase isoenzymes: characterization and functional effects of various phosphodiesterase inhibitors in vitro. Urology 45: 893-901, 1995.
105. Truss M, Ückert S, Stief CG, Kuczyk M, and Jonas U: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res 24: 123-128, 1996.
106. Truss M, Ückert S, Stief GC, Forssmann WG, and Jonas U: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrsuor smooth muscle. II. Effect of various PDE inhibitors on smooth muslce tone and cyclic nucleotide levels in vitro. Urol Res 24: 129-134, 1996.
107. Truss M, Stief CC, Uckert S, Becker AJ, Forssmann W-G, and Jonas U: Initial clinical experience with the selective phosphodiesterase (PDE)-I isoenzyme inhibitor vinpocetine in the treatment of urge-incontinence and low compliance bladder. J Urol 157: 187, 1997.